MOTS-c clinical trials: what human evidence actually exists

Last updated 2026-07-25

Has MOTS-c ever been tested in a human clinical trial?

No. Searching the published literature turns up zero completed, peer-reviewed human clinical trials of MOTS-c for metabolic health, weight, exercise performance, or aging. What exists instead is a fairly large stack of preclinical work: mouse models of obesity and insulin resistance ^[1], cell culture studies of muscle and cancer biology ^{[2] [3]}, and rodent models of everything from gestational diabetes to lung injury ^{[4] [5]}. That's not a knock on the science. It's just the stage the science is at. MOTS-c was discovered in 2015 in a paper that showed it "promotes metabolic homeostasis and reduces obesity and insulin resistance" in mice ^[1], and most of the mechanistic follow-up since then has stayed in mice, rats, and cultured cells. The closest thing to human clinical relevance in the current literature is a 2026 Sports Medicine review covering "Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance" ^[6], which addresses MOTS-c as one of several unapproved peptides being used off-label by athletes, without reporting a dedicated human trial of it. If you see a company or influencer citing a MOTS-c human trial, ask for the PubMed ID or the trial registry number. As of this writing, there isn't one to cite.

What has MOTS-c actually been shown to do, and in what model?

The founding finding is from Cell Metabolism in 2015: in mice, MOTS-c treatment improved insulin sensitivity and reduced diet-induced obesity, and the peptide's effects were tied to AMPK activation ^[1]. That's the paper the whole field cites, and it's mouse data, not human data. A second major paper, also in Cell Metabolism (2018), showed that MOTS-c translocates to the nucleus under metabolic stress and directly regulates nuclear gene expression, including antioxidant response genes, in cultured cells and mouse tissue ^[7]. A 2019 BioEssays review frames this as evidence MOTS-c acts as a genuine mitochondria-to-nucleus signal, more than a circulating hormone ^[8]. Beyond metabolism, the peptide has been studied in a wide scatter of disease models: ovarian cancer cells, where it suppressed tumor progression via a ubiquitination pathway ^[3]; gestational diabetes in rodents ^[4]; lung ischemia-reperfusion injury ^[5]; cardiopulmonary bypass lung injury ^[9]; allergic asthma airway models ^[10]; pulmonary fibrosis ^[11]; osteoarthritis cartilage models ^[12]; hepatitis B infection ^[13]; and skeletal muscle repair after cell membrane damage ^[14]. Every one of these is cell culture or animal work. None is a completed human trial.

Is there any human data on MOTS-c at all?

There's human-derived tissue and correlational data, but not interventional trial data. Some of the foundational MOTS-c papers measured circulating MOTS-c levels in human blood samples and correlated them with age, insulin resistance, or disease status. That's observational biomarker work, not a clinical trial where researchers gave people MOTS-c and measured outcomes. A 2023 Diabetes & Metabolism Journal paper reviews MOTS-c's proposed connections to diabetes and aging-related disease in humans ^[15], and a companion piece in the same journal covers the "exercise, mitohormesis" angle ^[16], but both are reviews synthesizing preclinical mechanisms, not trial reports. The practical upshot: nobody has published a randomized, placebo-controlled human trial measuring what injectable MOTS-c does to blood glucose, body composition, or muscle performance in real people. If you're being sold MOTS-c on the promise of a specific human trial result, that claim isn't backed by anything currently indexed on PubMed.

Is MOTS-c really "exercise in a pill"? What does the evidence say?

This is marketing language, not a research finding, and it's worth being precise about why. The actual science shows something narrower and more interesting: MOTS-c is a mitochondrial signal that goes up with exercise and that mimics some downstream effects of exercise training in mice, not that it replaces exercise for a person. A 2021 review in Biochimica et Biophysica Acta covers "Mitochondrial-derived peptides and exercise" ^[17] and a 2022 Diabetes & Metabolism Journal paper is titled "Exercise, Mitohormesis, and Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c)" ^[16], both describing MOTS-c as part of the mitohormesis response, the idea that mild mitochondrial stress (like exercise) triggers adaptive signaling. In mouse muscle tissue, MOTS-c has been shown to activate AMPK ^[1], bind and activate CK2 to modulate skeletal muscle function ^[18], promote muscle differentiation in vitro ^[2], reduce myostatin and muscle atrophy signaling ^[19], and protect against immobilization-induced muscle atrophy by suppressing lipid infiltration ^[20]. That's a real and consistent mechanistic story about muscle and mitochondrial biology, entirely in animal and cell models. It is not evidence that an injection substitutes for a treadmill session in a human being. Calling it "exercise in a pill" collapses a nuanced hypothesis about mitochondrial signaling into a slogan that no cited trial supports. Readers comparing this to dosing questions should look at MOTS-c dosage and how to take MOTS-c peptide for what protocols people are actually following, separate from what's proven.

What does the 2023 Frontiers in Endocrinology review actually conclude?

The 2023 review, titled "MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation" ^[21], is exactly what its title says: a review arguing MOTS-c is a promising candidate for future drug development, based on the accumulated preclinical mechanistic data. "Promising" and "proven" are different words, and the paper does not report new human trial data. It synthesizes findings across metabolic disease, aging biology, and the nuclear signaling role described in the 2018 Cell Metabolism paper ^[7]. A related 2023 paper in Metabolites, "MOTS-c Functionally Prevents Metabolic Disorders" ^[22], again reports on functional prevention in the context these MOTS-c papers use, which is rodent metabolic disease models, not a human disease prevention trial. Same for a 2025 Cardiovascular Drugs and Therapy piece asking "MOTS-c: Magical Molecule for Diabetic Cardiomyopathy?" ^[23], a review posing the question rather than a trial answering it with patient data. These reviews are useful for understanding where the field's excitement is coming from. They're not a substitute for trial data, and none of them claim to be.

What conditions is MOTS-c being studied for in animal models?

The range is broad, which is part of why MOTS-c gets so much attention: it shows up in nearly every organ system researchers have tested it in. Here's a summary table of representative findings, all preclinical.

Every row in that table is animal or cell data. That breadth is genuinely striking from a basic-science standpoint. It also means none of these applications has been tested in a person yet, and translating from mouse dose to human dose, or from cell culture concentration to injectable dose, is not a simple conversion.

Does MOTS-c have any downside signals in the research?

Yes, at least one finding worth taking seriously. A 2018 paper in Rejuvenation Research, "Mitochondrial-Derived Peptides Exacerbate Senescence" ^[29], reported that this class of peptides (which includes MOTS-c along with humanin and other mitochondrial-derived peptides) can, in certain contexts, worsen cellular senescence rather than reverse it. This cuts against the simple "MOTS-c fights aging" narrative and is a good example of why single mechanistic papers shouldn't be read as settled verdicts. The 2026 Sports Medicine review on unapproved peptide therapies ^[6] is also relevant here: it's specifically framed around safety and efficacy of peptides being used off-label by athletes and general consumers, which signals that regulators and clinicians researching this space see a real gap between what's marketed and what's been safety-tested in humans. No published paper in this set reports a completed human adverse event profile, dose-ranging safety study, or pharmacokinetic study for MOTS-c in people. That absence is itself the finding. It means anyone using MOTS-c today is doing so without the kind of safety data that supports an FDA-approved drug listed in Drugs@FDA.

Is MOTS-c FDA-approved, and can it legally be compounded?

MOTS-c is not an FDA-approved drug. It does not appear in the Drugs@FDA database of approved drug products ^[30]. That means there's no FDA-reviewed label, no approved indication, and no FDA-set dosing standard for it. Whether a compounding pharmacy can legally prepare it depends on federal bulk drug substance rules. Under 21 U.S.C. 353a, pharmacies compounding under section 503A can only use bulk drug substances that meet specific criteria, including appearing on the FDA's 503A Bulks List under 21 CFR 216.23 ^{[31] [32]}, or being a component of an FDA-approved drug, or meeting other narrow exceptions. FDA maintains a bulk drug substances page for 503A compounding ^[33] and a running list of nominated substances ^[34]. Outsourcing facilities compounding under 503B follow a separate list under 21 CFR 216.24 ^[35]. As of this writing, MOTS-c's regulatory status on these lists is something buyers should verify directly against FDA's current bulk substances page ^[33] rather than take on a seller's word, because these lists get updated and a peptide's status can change. This is also why the language a seller uses matters: FDA's rule on "intended uses" (21 CFR 201.128) ^[36] governs how a product can be marketed, and vague wellness claims don't substitute for approved indications.

Why hasn't MOTS-c gone through human trials yet?

A few honest reasons, none of them exotic. First, MOTS-c is a relatively young discovery, first characterized in the 2015 Cell Metabolism paper ^[1], so the field is still at the mechanism-mapping stage that most peptide hormones go through before anyone funds a Phase 1 trial. Second, running a human trial for an unapproved, unpatented-in-this-form peptide costs real money, and that funding typically comes from a pharmaceutical sponsor pursuing a specific drug application, which requires the kind of IND (Investigational New Drug) pathway that a wellness-market peptide sold direct-to-consumer doesn't go through. Third, the sheer breadth of preclinical findings (metabolic, muscular, cardiac, pulmonary, oncologic, viral) actually makes trial design harder, not easier: which indication do you pick first? Diabetes? Sarcopenia? Something else? Different research groups are clearly betting on different answers, which is part of why the literature reads more like a survey than a focused drug development program. For readers weighing this in practice, that means: treat mouse-model excitement and human evidence as two separate columns in your own notes, and don't let the volume of animal papers stand in for the one thing that's actually missing, a published human trial.

What should I actually take from this evidence gap?

Read the animal data as hypothesis-generating, not answer-giving. The mechanistic story (mitochondrial stress signal, AMPK activation, nuclear translocation under metabolic stress ^[7], mitohormesis link to exercise ^[16]) is coherent and interesting to a metabolic researcher. It is not the same thing as proof that a person injecting MOTS-c will see the same insulin sensitivity improvement a 2015 mouse study reported ^[1]. If you're a researcher tracking this space, the papers worth bookmarking are the two Cell Metabolism papers ^{[1] [7]}, the 2019 BioEssays mechanistic review ^[8], and the 2026 Sports Medicine safety review ^[6], because that last one is the closest thing to a human-context safety discussion currently published. If you're a consumer weighing whether to use it, the honest answer is that you're acting ahead of the trial data, not on top of it. That's a legitimate choice some people make with eyes open, similar to how many peptides move from bodybuilding and biohacker use into eventual clinical study. But it's worth being clear-eyed about which stage of that process MOTS-c is actually in right now. For dosing conventions people are following in absence of trial-derived standards, see MOTS-c dosage, the MOTS-c dosage calculator, and MOTS-c injection sites. MOTS-c Co's own reference pages track this same evidence honestly: start with the MOTS-c hub for the full mechanistic picture before deciding anything about use.

Where can I find a provider who actually reviews MOTS-c evidence before dispensing it?

If you decide to move forward despite the trial gap, the safer path runs through a licensed provider who reviews your labs and history before anything is dispensed, rather than a straight e-commerce checkout. MOTS-c Co's provider-reviewed route connects that clinical review step to a compounding pharmacy partner that actually prepares the product, since MOTS-c Co does not compound or manufacture anything itself. Whatever route you take, ask directly whether the source substance is sourced from a facility operating under the bulk drug substance rules described above ^{[31] [32] [33]}, and ask your provider to walk you through the animal-versus-human evidence distinction covered in this article, not around it. A provider willing to say "we don't have human trial data on this yet" is giving you more useful information than one who quotes you a mouse study as if it settles the question.

Frequently asked questions

Are there any completed MOTS-c clinical trials in humans?

No completed, published human clinical trials of MOTS-c appear in the PubMed literature as of 2026. The evidence base is mouse, rat, and cell-culture studies, starting with the foundational 2015 Cell Metabolism paper ^[1]. A 2026 Sports Medicine review ^[6] covers MOTS-c as an unapproved peptide used off-label, without reporting a dedicated human trial.

Is MOTS-c FDA approved?

No. MOTS-c does not appear as an approved drug product in the FDA's Drugs@FDA database ^[32]. It has no FDA-reviewed label, approved indication, or standardized human dosing established through the FDA approval process.

Does MOTS-c really work like exercise in a pill?

That phrase is marketing shorthand, not a study finding. Preclinical work links MOTS-c to mitohormesis, the exercise-triggered mitochondrial stress response, and shows AMPK activation and muscle effects in mice ^[1][16][17]. No published trial shows MOTS-c replicates exercise's effects in humans.

What did the original 2015 MOTS-c study actually find?

Published in Cell Metabolism, it found that MOTS-c "promotes metabolic homeostasis and reduces obesity and insulin resistance" in mice, tied to AMPK activation ^[1]. It's a mouse study; it did not test MOTS-c in humans.

Has MOTS-c been studied for muscle loss or atrophy?

Yes, in animal and cell models. Studies show MOTS-c reduces myostatin and atrophy signaling ^[20], promotes muscle differentiation in vitro ^[19], protects against immobilization-induced atrophy by suppressing lipid infiltration ^[21], and activates CK2 to modulate muscle function ^[18]. All are preclinical, not human trial results.

Is MOTS-c being researched for diabetes?

Extensively, in animal models. It's been studied for gestational diabetes ^[4], diabetic cardiomyopathy ^[24], diabetic liver fibrosis ^[26], and pancreatic islet cell senescence in diabetes progression ^[25]. A 2023 review connects MOTS-c to diabetes and aging-related disease broadly ^[15]. None of this is human trial data yet.

Are there safety concerns with MOTS-c?

A 2018 Rejuvenation Research paper found mitochondrial-derived peptides, including MOTS-c's class, can exacerbate cellular senescence in some contexts ^[31], cutting against the simple anti-aging narrative. No published human safety or adverse-event trial exists, which is itself the main safety concern for real-world use.

Can a pharmacy legally compound MOTS-c?

It depends on current FDA bulk drug substance list status. Compounding under 21 U.S.C. 353a requires the substance meet criteria under 21 CFR 216.23 (503A) or 216.24 (503B) ^[33][34][37]. Check FDA's current bulk substances page ^[35] directly rather than relying on a seller's claim, since these lists change.

What organs or conditions has MOTS-c been tested on in animal studies?

A very wide range: metabolism and obesity ^[1], bone ^[27], cartilage and osteoarthritis ^[28], lung injury and fibrosis ^[5][9][11], asthma ^[10], ovarian cancer cells ^[3], hepatitis B ^[13], muscle repair ^[14], and intervertebral disc cells ^[29]. All preclinical, none in completed human trials.

Why hasn't MOTS-c been tested in humans yet?

It's a relatively recent discovery (2015), and human trials typically need pharmaceutical sponsorship through an IND pathway, which an unapproved wellness-market peptide usually hasn't gone through. The breadth of preclinical findings across many organ systems also makes it unclear which single indication would anchor a first trial.

What's the difference between MOTS-c mouse data and human relevance?

Mouse studies establish mechanism and dose-response in a controlled biological system, but mouse metabolism, dosing, and physiology differ from human physiology enough that effects don't automatically transfer. Until a published human trial exists, mouse findings like reduced obesity and insulin resistance ^[1] should be read as hypothesis-generating, not as proof of human benefit.

Does research show MOTS-c has anti-cancer effects?

One 2024 study in Advanced Science found MOTS-c suppressed ovarian cancer progression in cell culture by affecting a USP7-LARS1 deubiquitination pathway ^[3]. This is a single cell-culture finding in one cancer type, not evidence of a general anti-cancer effect, and it has not been tested in human cancer patients.

Sources

1. PubMed, Cell Metabolism 2015 (PMID 25738459): MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance in mice, tied to AMPK activation
2. PubMed, Peptides 2022 (PMID 35842023): MOTS-c promotes muscle differentiation in vitro (cell culture)
3. PubMed, Advanced Science 2024 (PMID 39321430): MOTS-c suppresses ovarian cancer progression in cell culture via USP7-mediated LARS1 deubiquitination pathway
4. PubMed, Pharmacological Research 2022 (PMID 34798268): MOTS-c relieves hyperglycemia and insulin resistance in a gestational diabetes model
5. PubMed, Redox Biology 2025 (PMID 40403491): MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-dependent nuclear translocation
6. PubMed, Sports Medicine 2026 (PMID 41966639): Review of safety and efficacy of approved and unapproved peptide therapies including MOTS-c for athletic performance
7. PubMed, Cell Metabolism 2018 (PMID 29983246): MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress
8. PubMed, BioEssays 2019 (PMID 31378979): Review describing MOTS-c as a mitochondrial-encoded regulator of nuclear gene expression
9. PubMed, American Journal of Respiratory Cell and Molecular Biology 2025 (PMID 40035775): MOTS-c promotes glycolysis via AMPK-HIF-1α-PFKFB3 pathway to reduce cardiopulmonary bypass-induced lung injury
10. PubMed, International Immunopharmacology 2025 (PMID 40472776): MOTS-c attenuates airway barrier dysfunction in an allergic asthma model by inhibiting epithelial apoptosis
11. PubMed, Mitochondrion 2023 (PMID 37307934): MOTS-c identified as a potential anti-pulmonary fibrosis factor derived by mitochondria
12. PubMed, Free Radical Biology & Medicine 2025 (PMID 41043625): MOTS-c attenuates mitochondrial dysfunction and cartilage degradation in osteoarthritis via Nrf2-dependent mechanism
13. PubMed, Gut 2024 (PMID 37788894): MOTS-c has an antiviral role during hepatitis B infection via mitochondrial remodeling
14. PubMed, Theranostics 2024 (PMID 39267782): MOTS-c participates in plasma membrane repair by facilitating TRIM72 translocation to the membrane
15. PubMed, Diabetes & Metabolism Journal 2023 (PMID 36824008): Review connecting mitochondrial-encoded peptide MOTS-c to diabetes and aging-related diseases
16. PubMed, Diabetes & Metabolism Journal 2022 (PMID 35656563): Review linking MOTS-c to exercise-induced mitohormesis
17. PubMed, Biochimica et Biophysica Acta 2021 (PMID 34520826): Review of mitochondrial-derived peptides and their relationship to exercise
18. PubMed, iScience 2024 (PMID 39559755): MOTS-c modulates skeletal muscle function by directly binding and activating CK2
19. PubMed, American Journal of Physiology Endocrinology and Metabolism 2021 (PMID 33554779): MOTS-c reduces myostatin and muscle atrophy signaling
20. PubMed, American Journal of Physiology Endocrinology and Metabolism 2024 (PMID 38170165): MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration
21. PubMed, Frontiers in Endocrinology 2023 (PMID 36761202): Review calling MOTS-c a promising mitochondrial-derived peptide for therapeutic exploitation
22. PubMed, Metabolites 2023 (PMID 36677050): Review/study concluding MOTS-c functionally prevents metabolic disorders in preclinical models
23. PubMed, Cardiovascular Drugs and Therapy 2025 (PMID 40172798): Review examining MOTS-c's potential role in diabetic cardiomyopathy
24. PubMed, Experimental & Molecular Medicine 2025 (PMID 40855115): MOTS-c prevents pancreatic islet cell senescence to delay diabetes onset in a mouse model
25. PubMed, Scientific Reports 2025 (PMID 40425777): MOTS-c mimics exercise effects to combat diabetic liver fibrosis via Keap1-Nrf2-Smad2/3 pathway
26. PubMed, Frontiers in Physiology 2023 (PMID 37200834): Review of MOTS-c's role in regulation of bone metabolism
27. PubMed, Materials Today Bio 2025 (PMID 40510834): MOTS-c-modified peptide hydrogels enhance nucleus pulposus-derived stem cell activity for disc degeneration
28. PubMed, Autophagy 2026 (PMID 42153537): MOTS-c ameliorates lysosomal membrane permeability and improves survival of soft tissue transplantation in an animal model
29. PubMed, Rejuvenation Research 2018 (PMID 30058454): Mitochondrial-derived peptides, including MOTS-c's class, can exacerbate cellular senescence in certain contexts
30. FDA, Drugs@FDA database: MOTS-c does not appear as an FDA-approved drug product
31. Cornell Law School, 21 U.S.C. 353a: Pharmacy compounding under section 503A requires bulk substances to meet specific federal criteria
32. eCFR, 21 CFR 216.23 (503A Bulks List): Defines the final 503A bulk drug substances list governing what compounders may use
33. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA's current page for verifying bulk drug substance status for 503A compounding
34. FDA, Bulk Drug Substances Nominated for 503A Compounding (current list): FDA's running list of nominated bulk drug substances including their review status
35. eCFR, 21 CFR 216.24 (503B Bulks List): Defines the bulk drug substances list governing outsourcing facilities compounding under 503B
36. eCFR, 21 CFR 201.128: Defines how a product's intended use is determined for FDA marketing and labeling purposes